VENUSREM

Venus Remedies Limited

Pharmaceutical formulations and API for injectables and allied therapy areas

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

venusremedies.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1650.70
Market cap
2,207 Cr
Stock P/E
19.0
P/B
3.32
ROE (FY26)
15.5%
ROCE (FY26)
20.2%
Operating margin (FY26)
15.8%
OCF / EBITDA (FY26)
105.8%
OCF / EBITDA (3Y)
103.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Venus Remedies is a pharmaceutical company with its corporate office and Unit I in Panchkula, Haryana, and a wholly owned subsidiary in Germany.

Company snapshot

74thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓103% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales168 Cr143 Cr195 Cr109 Cr167 Cr177 Cr195 Cr132 Cr193 Cr180 Cr259 Cr179 Cr
Operating expenses (approx.)150 Cr131 Cr176 Cr97 Cr163 Cr159 Cr166 Cr122 Cr162 Cr143 Cr196 Cr145 Cr
EBITDA18 Cr12 Cr19 Cr11 Cr5 Cr18 Cr29 Cr10 Cr31 Cr38 Cr63 Cr34 Cr
OPM %10.6%8.4%10.0%10.4%2.9%10.4%14.9%7.7%16.1%20.8%24.4%19.1%
Other income3 Cr2 Cr4 Cr2 Cr11 Cr2 Cr7 Cr9 Cr2 Cr3 Cr5 Cr3 Cr
Interest0.06 Cr0.07 Cr0.02 Cr0.02 Cr0.02 Cr0.01 Cr0.01 Cr0.01 Cr0.01 Cr0.01 Cr0.01 Cr0 Cr
Depreciation6 Cr7 Cr6 Cr6 Cr6 Cr5 Cr5 Cr6 Cr6 Cr7 Cr7 Cr7 Cr
Profit before tax14 Cr8 Cr17 Cr7 Cr9 Cr25 Cr28 Cr13 Cr26 Cr33 Cr62 Cr30 Cr
Tax %30.7%12.0%39.9%82.2%61.3%21.2%25.3%23.9%24.0%23.6%22.9%23.5%
Net profit10 Cr7 Cr11 Cr1 Cr4 Cr20 Cr21 Cr10 Cr20 Cr26 Cr47 Cr23 Cr
EPS (₹)₹7.44₹5.13₹7.86₹0.92₹2.63₹14.66₹15.71₹7.18₹15.06₹19.14₹35.53₹17.18

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales400 Cr372 Cr322 Cr341 Cr548 Cr599 Cr556 Cr601 Cr648 Cr770 CrSign in free for the trailing twelve months
Operating expenses (approx.)349 Cr333 Cr289 Cr301 Cr494 Cr537 Cr495 Cr542 Cr584 Cr622 CrSign in free for the trailing twelve months
EBITDA51 Cr39 Cr33 Cr41 Cr54 Cr62 Cr60 Cr60 Cr64 Cr147 CrSign in free for the trailing twelve months
OPM %12.7%10.6%10.1%12.0%9.8%10.4%10.8%9.9%9.8%19.1%Sign in free for the trailing twelve months
Other income2 Cr2 Cr6 Cr5 Cr20 Cr8 Cr10 Cr12 Cr21 Cr13 CrSign in free for the trailing twelve months
Interest34 Cr35 Cr25 Cr13 Cr13 Cr0.48 Cr0.29 Cr0.09 Cr0.07 Cr0.04 CrSign in free for the trailing twelve months
Depreciation40 Cr34 Cr34 Cr32 Cr35 Cr34 Cr32 Cr26 Cr23 Cr26 CrSign in free for the trailing twelve months
Profit before tax-22 Cr-28 Cr-30 Cr-8 Cr49 Cr36 Cr38 Cr45 Cr69 Cr134 CrSign in free for the trailing twelve months
Tax %21.1%-11.5%3.9%-24.4%-27.2%-11.9%29.9%36.2%34.2%23.4%Sign in free for the trailing twelve months
Net profit-17 Cr-31 Cr-29 Cr-10 Cr62 Cr41 Cr27 Cr28 Cr45 Cr103 CrSign in free for the trailing twelve months
EPS (₹)₹-14.88₹-24.87₹-23.15₹-8.10₹50.04₹30.86₹19.88₹21.31₹33.90₹76.89Sign in free for the trailing twelve months
Dividend payout %————0.0%0.0%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital12 Cr12 Cr12 Cr12 Cr12 Cr13 Cr13 Cr13 Cr13 Cr13 Cr
Reserves376 Cr350 Cr320 Cr311 Cr388 Cr427 Cr447 Cr474 Cr548 Cr650 Cr
Borrowings281 Cr259 Cr229 Cr158 Cr51 Cr43 Cr42 Cr41 Cr2 Cr—
Other liabilities95 Cr130 Cr171 Cr157 Cr104 Cr97 Cr98 Cr98 Cr153 Cr190 Cr
Total liabilities765 Cr751 Cr733 Cr638 Cr556 Cr580 Cr601 Cr627 Cr716 Cr854 Cr
Fixed assets (net)213 Cr209 Cr196 Cr184 Cr165 Cr153 Cr137 Cr133 Cr125 Cr125 Cr
CWIP66 Cr65 Cr65 Cr25 Cr25 Cr25 Cr26 Cr21 Cr26 Cr51 Cr
Investments——————20 Cr19 Cr84 Cr238 Cr
Inventories141 Cr138 Cr143 Cr141 Cr120 Cr126 Cr120 Cr122 Cr100 Cr129 Cr
Trade receivables47 Cr47 Cr38 Cr31 Cr32 Cr39 Cr77 Cr81 Cr112 Cr103 Cr
Cash & bank4 Cr4 Cr2 Cr2 Cr29 Cr43 Cr21 Cr49 Cr58 Cr25 Cr
Other assets294 Cr288 Cr289 Cr255 Cr185 Cr194 Cr200 Cr202 Cr210 Cr182 Cr
Total assets765 Cr751 Cr733 Cr638 Cr556 Cr580 Cr601 Cr627 Cr716 Cr854 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity59 Cr51 Cr45 Cr77 Cr133 Cr41 Cr37 Cr37 Cr86 Cr156 Cr
Cash from investing-18 Cr-12 Cr-11 Cr-5 Cr56 Cr-17 Cr-51 Cr-7 Cr-76 Cr-182 Cr
Cash from financing-44 Cr-39 Cr-35 Cr-73 Cr-162 Cr-9 Cr-0.57 Cr-1 Cr-1 Cr-3 Cr
Net cash flow-4 Cr0.42 Cr-1 Cr-0.74 Cr26 Cr14 Cr-22 Cr28 Cr9 Cr-32 Cr
Free cash flow (OCF − Capex)41 Cr39 Cr35 Cr69 Cr133 Cr27 Cr29 Cr24 Cr68 Cr118 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %1.9%1.3%-0.8%1.1%13.6%7.6%7.6%8.5%12.3%20.2%
ROE %-4.4%-8.5%-8.6%-3.1%15.4%9.2%5.8%5.8%8.1%15.5%
Debtor days43464333212350496349
Inventory days229246274306126120137129105121
Days payable485269807552584796106
Cash conversion cycle22424024825972911291317264
OCF / EBITDA %116.2%130.3%139.4%188.7%246.6%66.0%60.8%62.6%136.1%105.8%
OCF / EBITDA % (3 years)——126.9%154.0%200.6%159.9%119.4%63.2%87.5%103.4%
Debt / equity0.720.710.690.490.130.100.090.080.0030—
Current ratio1.321.141.011.322.403.003.914.533.312.44
Net debt / EBITDA5.47—6.97———0.35-0.13-0.88-0.17